We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Puricore | PURI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 28.75 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 28.75 | 28.75 |
| Top Posts |
|---|
Posted at 29/3/2016 16:08 by love it mm's must be delaying the trade.29 March 2016 PuriCore plc ("PuriCore" or the "Company") Director Dealing 29 March 2016 - PuriCore plc (AIM: PURI), announces that, Alex Martin, Chief Executive Officer and Executive Director of the Company, today purchased ordinary shares of 10p each in the share capital of the Company ("Shares"). % of Number Purchase Shareholding issued of Shares price following share Name Date purchased purchased of Shares the purchase capital 29 March Alex Martin 2016 100,000 28p 100,000 0.20% |
Posted at 08/2/2016 13:58 by danwaits Riddle, before bigging up any outfit, I think that it's always best to take a peek at past and current performance, especially as early investors in this POS are down almost 95% on their original investments.Two years ago, Puri had two revenue generating divisions; the loss making supermarket business and the endoscopy business which was generating $2m PBT. So, guess which one did they sold? Now they claim growing revenues in the remaining retail side (due mainly to one-off sales of dosing units), but most likely the business remains unprofitable. Solution - "Let's abandon all existing revenue streams and get into the prescription drugs business, which we know absolutely FA about, apart from what some consultant chappies have told us. And let's also recruit some suitable souls to help us spend the last of our share-holders funds as we chase some blue-sky dreams. Gosh, we're brilliant altogether, what spiffingly wonderful money managers we are" |
Posted at 14/10/2015 17:27 by love it This just might get a bit more interesting.14 October 2015 PuriCore plc ("PuriCore" or the "Company") Director Dealing 14 October 2015 - PuriCore plc (AIM: PURI), an international company focused on applying its proprietary hypochlorous acid platform technology to unmet needs in human health, announces that, on 14 October 2015, the Director named below notified the Company that he had purchased ordinary shares of 10p each in the share capital of the Company ("Shares"). % of Number Purchase Shareholding issued of Shares price following the share Name Date purchased purchased of Shares purchase capital Daniel Hegglin Non-Executive Director 13 October 2015 500,000 18p 5,909,091 11.79% |
Posted at 19/3/2015 11:14 by danwaits Because it's not very profitable gfrae, despite the management's best efforts to rectify the problems.Imagine you have on big machine at a central base which churns out gallons of product, which are packaged as RTU sprays, or in HC's which can be diluted as and when a customer requires them. These stable, long life products can be shipped out to the retail company's central distribution warehouse and delivered to each outlying store from there. That is the very model that PURI want for their products. The retailers however, want machines in each store, continuously churning out fresh product at source. This means that PURI must install several machines, often located hundreds of miles apart and service them regularly, whilst also supplying the base chemical product at a much lower margin than the pre-packaged products. The customer is not always right, especially when they expect the supplier to continue committing slow hara-kiri. Today's RNS suggests that the big customers are still dictating terms, despite the company's extreme efforts in the past while to re-transition the business. |
Posted at 19/3/2015 10:34 by gfrae Dan,why would'nt you invest in PURI if you think the product is so good? Don't you think they'll make any money out of it? G. |
Posted at 19/3/2015 10:27 by danwaits Whilst the announcement of any new sales contract can only be good news, there's some interesting detail in this morning's RNS. It's obvious that the in-house Sterilox system is not too profitable for PURI, due to the high labour costs involved in servicing the units at a retail outfit's multiple sites. Which is why they announced that the were repositioning the business towards the HC (high concentrate) or RTU (ready-to-use) model. This made perfect sense, however this morning's news informs us that the major retailers are saying "We don't want HC or RTU, we want our own mixing units in-house and if you don't want to give it to us, we'll be on to Ecolab or Diversey like a hot snot". So, PURI are stuck with the busy fools business model, which can only be solved by astute marketeering and logistics management.Me, I LOVE the product and think it has amazing potential, but wouldn't for a minute be tempted to invest in PURI. |
Posted at 07/11/2014 07:49 by stylesip NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION PuriCore plc("PuriCore" or the "Company")Proposed Cancellation of Listing on the Official List, Admission to AIMand Notice of General Meeting 7 November 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, announces today that the Board is proposing to cancel the listing of the Company's Ordinary Shares on the premium segment of the Official List and their trading on the Main Market and to apply for admission of the Ordinary Shares to trading on AIM. The Board believes key advantages to be gained by this move include that a listing on AIM: · Should afford the most appropriate exchange for trading in the Company's Shares by providing a market and environment more suited to the Company's current size and to achieving its corporate objectives· May increase the appeal of the Company to new retail investors while continuing to appeal to institutional investors· Offers greater flexibility to the Company, particularly with regard to corporate transactions· Establishes a more cost-effective platform on which to maintain the Company's publicly traded status· Should reduce time and cost of compliance whilst maintaining appropriate disclosure and corporate governance practices Michael Ashton, Chief Executive Officer of PuriCore, commented: "As previously announced, the Company has initiated a strategic and operational review of the business. In parallel with this review, the Board considered how to increase the appeal of the Company to new investors and which was the right platform on which to maintain the Company's publicly traded status. After careful consideration, the Board believes that the proposed move to AIM will afford the most appropriate exchange for trading in the Company's Shares by providing a market and environment more suited to the Company's current size and to achieving the advantages listed above. "The Board has advanced the strategic and operational review and plans to announce further information before the year end." A circular dated, 7 November 2014, (the "Circular"), which contains a Notice convening a General Meeting, to be held at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD at 11.00 a.m. on 24 November 2014, will be posted to Shareholders today. The Circular outlines the reasons for the proposed Delisting and Admission and explains why the Board believes such proposals to be in the best interests of the Company and its Shareholders as a whole. At the General Meeting, the Company will seek Shareholder approval for the proposed cancellation of admission to the premium segment of the Official List and to trading on the London Stock Exchange's Main Market for listed securities ("Delisting") and the intention to apply for admission to trading on AIM ("Admission") will be detailed. Extracts from the letter from the Chairman contained within the Circular and the expected timetable of principal events are reproduced below. The Circular will be made available on the Company's website at www.puricore.com and shortly will be submitted to the National Storage Mechanism where it will be available at www.morningstar.co.u |
Posted at 01/7/2014 14:08 by mctmct Paul Scott points out that today's completion of the sale means that PURI now have cash equivalent to about 75% of market cap. He suggests that at least half should be returned to shareholders. |
Posted at 20/6/2013 08:07 by stylesip News Alert for Puricore .RNS Number : 4438HPuriCore Plc20 June 2013 ?PuriCore plc ("PuriCore" or the "Company")20 June 2013 PuriCore Signs Major US Deal $13.5 Million Agreement Launches Strategically Important ProduceFresh Bottled Concentrate PuriCore (LSE: PURI), the global company focused on advancing human health through the control of infectious pathogens, today announces it has signed a sales agreement for its new ProduceFresh bottled concentrate valued at an estimated $13.5 million with a top-three US supermarket retailer. Under the terms of the agreement, the retailer will use ProduceFresh across all of its stores for a committed term of approximately four years commencing in Q3 2013. PuriCore expects this revenue will be booked in the Company's financial accounts from 2013 through to 2017. ProduceFresh is the most recent product offering in the PuriCore supermarket retail portfolio, which includes the Sterilox® Fresh System and FloraFresh® bottled concentrate. Like the Sterilox Fresh System, new ProduceFresh bottled concentrate reduces the risk of the transmission of foodborne illnesses in retail supermarkets and reduces inventory shrink. This new offering provides retail customers with greater choice according to their business model, either on-site generation of Sterilox Fresh solution or delivery of ProduceFresh bottled concentrate solution for on-site dilution. This additional bottled product provides PuriCore with a long-term recurring revenue stream and reduces the costs of manufacturing, installation, and servicing. Michael Ashton, Executive Chairman, said:"ProduceFresh is an important expansion to our product portfolio as this sales agreement clearly demonstrates, offering customers a choice that best addresses their particular business needs. The ProduceFresh offering also enables us to increase our market reach to retail customers and foodservice operators whose businesses are better suited to a bottled product." |
Posted at 17/5/2013 08:00 by stylesip PuriCore plc("PuriCore" or the "Company")17 May 2013 Interim Management StatementBalance sheet significantly improved PuriCore (LSE: PURI), the water-based clean technology company, today announces its Interim Management Statement for the period from 1 January 2013 to 17 May 2013 (which incorporates information in relation to the financial performance of the business for the first quarter being from 1 January 2013 to 31 March 2013). Q1 Financial Highlights (unaudited)· Group revenue down 23.7% (23.2% at constant currency) to $10.9m (Q1 2012: $14.3m)§ Supermarket Retail revenue down 51.0% to $3.6m (Q1 2012: $7.4m)§ Endoscopy revenue down 4.9% (3.9% at constant currency) to $6.2m (Q1 2012: $6.6m)§ Wound Care revenue up 188.5% to $1.1m (Q1 2012: $0.4m)· EBITDA* profitable in Endoscopy and Wound Care businesses· Gross profit margin improved by 4.6 percentage points· Gross cash of $4.3m at 31 March 2013 * Earnings before interest, tax, depreciation, and amortisation. Business and Operational Highlights· Strengthened the balance sheet§ Converted 95% of the £7.95m of Convertible Loan Notes§ Raised approximately £2.3m (before expenses) in a placingFood & Agriculture· Signed a $14m Sterilox Fresh agreement with a top-five US supermarket retailerHealth Sciences· Received US FDA regulatory clearance for Vashe Skin and Wound Hydrogel formulation itch related to atopic dermatitis· Formed marketing partnership with Onset Dermatologics for new Vashe-based dermatologic hydrogel products· Formed marketing partnership with SteadMed Medical in April for marketing of Vashe Wound Therapy in the US, Canada, and Mexico Michael Ashton, Executive Chairman, said:"We significantly improved our balance sheet in the quarter. Comparative revenue results, however, were affected by very high installations of Sterilox Fresh Systems during Q1 2012 as well as the receipt of a $14 million Sterilox Fresh contract that was not signed and therefore not delivering revenue until Q2 2013. This agreement and other forthcoming orders in the Supermarket Retail business plus our expansion into the floral departments will continue to drive revenues in the Supermarket Retail segment for the full year. With these sales coupled with our recently signed marketing partnerships in the Wound Care and Dermatology therapeutic areas and an increasing revenue stream from our Endoscopy business, the Directors remain confident in the prospects for the Company going forward." Business ReportDuring the period, the Company significantly strengthened its balance sheet. As announced in December 2012 and approved by shareholders in January, the Company restructured 95.28% of the £7.95 million of Convertible Loan Notes, which mature on 31 December 2013. In addition, the Company completed a placing, announced in December 2012 and approved by shareholders in January, raising approximately £2.3 million in new shares (before expenses) at a price of 43 pence per Ordinary Share. Revenue for the Company decreased 23.7% to $10.9 million (23.2% at constant currency) in the first quarter of 2013 (Q1 2012: $14.3 million). This variance primarily was due to timing of orders in the Supermarket Retail business. Gross profit margin for the Company improved by 4.6 percentage points due to strong results in Wound Care and improving margins in Endoscopy. The Endoscopy and Wound Care businesses were EBITDA profitable in the period. Cash and cash equivalents were $4.3 million as at 31 March 2013. Food & AgricultureIn the Supermarket Retail business, revenue decreased 51% to $3.6 million (Q1 2012: $7.4 million) as expected as the Company prepared to commence installing in Q2 2013 Sterilox Fresh Systems as part of the $14 million agreement with a top-five US supermarket retailer. Under the terms of the agreement, the retailer will broadly implement Sterilox Fresh across its enterprise and has agreed to a six-year warranty agreement. Revenue will be recognised on the agreement beginning in Q2 2013, and the Company expects the majority of the system revenue will be recorded in the 2013 financial accounts. The remaining revenue will be recognised over the term of the warranty. Health SciencesIn the Endoscopy business, revenue decreased 4.9% (3.9% at constant currency) to $6.2 million (Q1 2012: $6.6 million) whilst the business remained EBITDA profitable for the quarter. The Wound Care business was EBITDA profitable with revenue increasing 188.5% to $1.1 million (Q1 2012: $0.4 million). In February, PuriCore announced that it had received US FDA regulatory clearance for Vashe Skin and Wound Hydrogel formulation for the management and relief of pain, burning, and itching experienced with various dermatoses including atopic dermatitis. The clearance was a key milestone in PuriCore's partnership with Onset Dermatologics, a leader in the development and commercialisation of prescription dermatology products, for the sale of Vashe-based dermatology products, which was announced in March. The agreement includes upfront payments and double-digit royalty payments on future sales of Aurstat Anti-Itch Hydrogel and Aurstat Kit. Onset Dermatologics commenced marketing and distributing this new Vashe-based formulation as Aurstat Anti-Itch Hydrogel and as a component of Aurstat Kit exclusively in the US. All intellectual property related to the Vashe hydrogel formulation remains with PuriCore. In April, PuriCore announced a marketing partnership with SteadMed Medical, a leading marketer of acute and chronic wound care products, to commercialise Vashe Wound Therapy in the US, Canada, and Mexico. Vashe will be an integral part of the SteadMed comprehensive protocol of care for acute and chronic wounds and burns, targeting wound care centres, hospitals, and home health agencies. This agreement will expand marketing reach for the Vashe product through SteadMed's experienced sales, marketing, and clinical teams. Under the terms of the multi-year agreement, PuriCore received an upfront payment of $500,000 and will receive royalties in the high teens based on sales volumes. All intellectual property related to Vashe remains with PuriCore. This information is provided by RNSThe company news service from the London Stock Exchange END IMSARMFTMBIBMAJ |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
